- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00422786
Phase II Study of CAP-232 in Patients With Refractory Metastatic Renal Cell Carcinoma
A Multi-Centre, Open Label, Phase II Study of the Safety, Efficacy and Pharmacokinetic (PK) Profile of CAP-232 Administered Through Continuous Intravenous Infusion in Patients With Metastatic Kidney Cancer
Study Overview
Detailed Description
This was a multi-center, open label, single arm study. Approximately 40 patients were initially planned to be recruited.
Each patient was to receive a treatment cycle consisting of CAP-232 via continuous IV infusion over 21 days at 0.48 mg/kg/day followed by a 7-day rest period. Treatment cycles to be repeated in the absence of disease progression or unacceptable toxicity.
Quality of Life questionnaires were to be administered at baseline, after each visit and at the end of the study.
Signs and symptoms of adverse events were closely monitored during treatment cycles. Safety laboratory measures were done at Screening, during the 72hr hospitalization (first cycle), at every interim visit , and at the end of the study. A follow-up safety visit was to be scheduled at least 30 days after the end of treatment.
CAP-232 plasma levels were also determined.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Montpellier, France, 34298
- CRLC Val d'Aurelle Paul-Lamarque
-
St-Priest en Jarez, France, 42270
- Institut de Cancérologie de la Loire
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically confirmed stage IV kidney clear cell carcinoma.
- Confirmed progressive disease after receiving a previous systemic therapy, including at least one line of standard of care.
- Measurable disease
- Age >18 years.
- Life expectancy of greater than 3 months.
- At least 5 years free of any other cancer(s). Basal cell carcinoma, provided that is neither infiltrating nor sclerosing and carcinoma in situ of the cervix, is acceptable.
- ECOG performance status 2 or lower (Karnofsky 60%).
- Normal organ and marrow function
- Adequate contraception prior to study entry and for the duration of study participation.
- Ability to understand and have the willingness to sign a written informed consent document.
- Ability to receive central vein access catheter and manage an infusion pump.
- Women of child bearing potential must have a negative serum pregnancy test.
Exclusion Criteria:
- Anti-cancer therapy within 4 weeks prior to entering the study
- Investigational agents less than 30 days prior to enrollment in the study.
- Known brain metastases
- History of allergic reactions attributed to compounds of similar composition to CAP-232.
- Past or current cancer other than kidney cancer, except for: Curatively treated non-melanoma skin cancer, In situ carcinoma of the cervix, Other cancer curatively treated and with no evidence of disease for at least 5 years
- Uncontrolled intercurrent illness /social situations that would limit compliance with study requirements.
- Breastfeeding
- Patients previously enrolled into this study and subsequently withdrawn
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CAP-232
Continuous IV infusion over 21 days at 0.48 mg/kg/day followed by a 7-day rest period.
|
Continuous IV infusion over 21 days at 0.48 mg/kg/day followed by a 7-day rest period
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
The primary efficacy parameter was the response rate based on RECIST criteria after 3 cycles
|
Secondary Outcome Measures
Outcome Measure |
---|
Quality of life
|
Safety (through clinical and biological evaluations)
|
Other efficacy parameters (progression-free survival rate, time to progression and overall survival)
|
Pharmacokinetic (PK) characteristics of the first 15 recruited patients
|
Biological modulation (through potential blood and/or urine biomarkers including M2PK)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Aline Guillot, MD, Institut de Cancérologie de la Loire, Dpt Oncologie Médicale, Saint-Priest en Jarez, France
- Principal Investigator: Damien Pouessel, MD, CRLC Val d'Aurelle Paul-Lamarque, Montpellier, France
Publications and helpful links
General Publications
- Tejeda M, Gaal D, Hullan L, Hegymegi-Barakonyi B, Keri G. Evaluation of the antitumor efficacy of the somatostatin structural derivative TT-232 on different tumor models. Anticancer Res. 2006 Sep-Oct;26(5A):3477-83.
- Tejeda M, Gaal D, Hullan L, Csuka O, Schwab R, Szokoloczi O, Keri G. A comparison of the tumor growth inhibitory effect of intermittent and continuous administration of the somatostatin structural derivative TT-232 in various human tumor models. Anticancer Res. 2006 Jul-Aug;26(4B):3011-5.
- Gyergyay F, Gödény M, Sármay G, Kralovanszky J, Papp E, Gergye M, Vincze B, Kéri G, Bodrogi I : Antitumor activity and pharmacology of TT-232 (a novel somatostatin structural derivative) in malignant melanoma patients JCO, 2004 ASCO Annual Meeting Proceedings Vol 22, No 14S (July 15 Supplement), 2004: 3151
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CTP_CAP001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carcinoma, Renal Cell
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Sarcomatoid Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | Unresectable Renal Cell... and other conditionsUnited States
-
Australian and New Zealand Urogenital and Prostate...RecruitingRenal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Papillary Renal Cell Carcinoma Type 1 | Papillary Renal Cell Carcinoma Type 2 | Chromophobe Renal Cell Carcinoma | Xp11.2 Translocation-Related Renal Cell CarcinomaAustralia
-
National Cancer Institute (NCI)CompletedClear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedClear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Type 1 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell CarcinomaUnited States, Taiwan, Australia
-
Bradley A. McGregor, MDBristol-Myers Squibb; ExelixisRecruitingRenal Cell Carcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma | Collecting Duct Renal Cell Carcinoma | Translocation Renal Cell Carcinoma | Unresectable Advanced Renal Cell Carcinoma | Metastatic Ncc Renal Cell CarcinomaUnited States
-
Jonsson Comprehensive Cancer CenterBeiGene; Driven To CureWithdrawnMetastatic Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8 | Papillary Renal Cell Carcinoma | Collecting Duct Carcinoma | Unresectable Renal Cell Carcinoma | Hereditary Leiomyomatosis and Renal Cell Carcinoma | Clear Cell Papillary Renal Neoplasm | Hereditary Papillary Renal Cell Carcinoma and other conditionsUnited States
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingChromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma | Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma | Fumarate Hydratase Deficient Renal Cell Carcinoma | Succinate Dehydrogenase Deficient Renal Cell Carcinoma | Collecting Duct Renal...United States
-
Australian and New Zealand Urogenital and Prostate...Bristol-Myers SquibbActive, not recruitingRenal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Papillary Renal Cell Carcinoma Type 1 | Papillary Renal Cell Carcinoma Type 2 | Chromophobe Renal Cell Carcinoma | Xp11 Translocation CarcinomaAustralia
-
Peloton Therapeutics, Inc.Active, not recruitingKidney Cancer | Renal Cell Carcinoma | Renal Cancer | Renal Cell Carcinoma (RCC) | Renal Cell Cancer Metastatic | Kidney | Clear Cell Renal Cell Carcinoma (ccRCC) | Renal Cell Carcinoma Recurrent | Renal Cell Cancer, RecurrentUnited States
-
AmgenCompletedRenal Cell Carcinoma | Clear Cell Renal Cell Carcinoma | Clear Cell Renal Carcinoma | Renal Cell AdenocarcinomaFrance, United States, Germany
Clinical Trials on CAP-232
-
Thallion PharmaceuticalsTerminatedMelanomaUnited States, Canada
-
Kartos Therapeutics, Inc.TerminatedSmall Cell Lung Carcinoma | Small-cell Lung Cancer | Small Cell Lung Cancer Extensive Stage | Small Cell Lung Cancer RecurrentGermany, Spain, France, Australia, United States, Korea, Republic of, Hungary
-
Kartos Therapeutics, Inc.CompletedCancer | Glioblastoma | Multiple Myeloma | Advanced Solid Tumors | Oncology | Tumors | Advanced Malignancy | Oncology PatientsUnited States, France, Netherlands
-
Protagonist Therapeutics, Inc.Completed
-
Kartos Therapeutics, Inc.UnknownPolycythemia VeraUnited States, Poland, Spain, Germany, Hungary, France
-
Kartos Therapeutics, Inc.GOG Foundation; European Network of Gynaecological Oncological Trial Groups...RecruitingEndometrial CancerUnited States, Austria, Spain, Israel, Denmark, Sweden, Slovenia, Finland, Georgia, Italy, Romania, Poland, Estonia, Hungary, Lithuania, Norway
-
Kartos Therapeutics, Inc.RecruitingPrimary Myelofibrosis (PMF) | Post-Polycythemia Vera Myelofibrosis (Post-PV-MF) | Post-Essential Thrombocythemia Myelofibrosis (Post-ET-MF)United States, Mexico, Bulgaria, Poland, Russian Federation, Belarus, Georgia, South Africa, Ukraine
-
National Cancer Institute (NCI)NRG OncologyActive, not recruitingSoft Tissue Sarcoma | Resectable Soft Tissue SarcomaUnited States
-
Kartos Therapeutics, Inc.RecruitingMyelofibrosisUnited States, France, Australia, Spain, Germany, Bulgaria, Israel, Italy, Poland
-
3MEurotrials Brasil Consultores Cientificos LtdaCompleted